Post-Marketing Surveillance Data of Adverse Events Following Immunization with Human Rabies Vaccine — China, 2021–2024

What is already known about this topic? Human rabies vaccine has been in use for many years and has played a vital role in rabies prevention and control in China. What is added by this report? From 2021 to 2024, the overall reported rate of adverse events following immunization (AEFI) with human rabies vaccine was 18.57 per 100,000 doses, of which 96.29% were common vaccine reactions. Rare vaccine reactions occurred at a rate of 0.49 per 100,000 doses; allergic rash was the most frequently reported rare reaction and usually was non-serious. The rate of rare and serious vaccine reactions was 0.07 per 100,000 doses. What are the implications for public health practice? Human rabies vaccine, one of the most commonly used non-program vaccines in China, its AEFI rate fell within an acceptable range. Continued AEFI surveillance is essential for evaluating the post-marketing immnization safety of this vaccine.